Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD. Phase I in healthy volunteers has been completed and a POC trial in ulcerative colitis patients is in progress.
Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers has been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and NASH. Phase I studies in healthy volunteers are in progress.
Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending. A POC trial in asthmatics has been completed with positive results. Phase II clinical in mild to moderate asthmatics are in progress.
Dual Adenosine A2a receptor antagonist / Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of tumors, especially for “cold tumors”, as for example colon cancers. A Phase I dose escalation study in patients with biopsiable solid tumors is in progress.
Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015 and is facing Phase II clinical trials in nine different tumor types.